In 2026 the Trump administration paired tariff threats on imported drugs with voluntary Most Favored Nation pricing deals, while FDA and DOJ sharply increased marketing and fraud enforcement. That matters because these moves link what patients pay, what ads they see, and what prescribers can be paid.
Most Favored Nation pricing means the U.S. would pay the lowest price a drugmaker charges in other wealthy countries. The administration used that goal to push discounts, domestic manufacturing, and a new direct-purchase site.
Table of Contents
- How do the new drug tariffs and price deals work?
- Why are prescription drug ads facing tougher FDA action?
- What happened with compounded GLP-1 telehealth marketing?
- How is DOJ pursuing health-care fraud and kickbacks?
- What limits could reduce the promised savings?
How do the new drug tariffs and price deals work?
On April 2, 2026, President Trump signed an executive order imposing 100% tariffs on imported branded drugs unless makers sign pricing deals or commit to U.S. manufacturing, according to Reuters in the April tariff order. Generic drugs received a slower schedule: 0% starting Aug. 1, 2026 for two years, then 100% for one year and 200% after, Reuters reported in the generic tariff timeline.
Since late 2025 the administration reached voluntary pricing deals with 17 large drugmakers including Pfizer, Eli Lilly and Novo Nordisk, with Pfizer offering up to 85% discounts through TrumpRx.gov. Those agreements exchange lower listed prices or U.S. investment for tariff relief. For shoppers, the link is direct: a tariff exemption can depend on whether a company stays in a pricing deal. A company that leaves a deal could face the tariff instead.
Why are prescription drug ads facing tougher FDA action?
FDA launched a direct-to-consumer ad crackdown on Sept. 9, 2025 after a Trump memorandum. The agency sent about 100 cease-and-desist orders plus thousands of notices, then 28 prescription-drug promotion warning or untitled letters through August 2026.
That letter total was over four times any full year from 2020 to 2024, according to eMarketer in the FDA ad-enforcement review. FDA is also looking beyond explicit claims to implied benefits, visuals, influencer posts, and omitted risk information. Patients should treat polished drug ads as marketing, not medical advice. Compare any claim about benefits, speed, safety, or who should use a drug with the written label and a clinician.
What happened with compounded GLP-1 telehealth marketing?
On March 3, 2026, FDA sent 30 warning letters to telehealth firms marketing compounded GLP-1 products for false or misleading efficacy and risk claims under misbranding rules. Another 25 letters followed in June, affecting telehealth marketers and compounding pharmacies.
📨 Get Free Accountability Coverage Alerts
Free · No spam · Unsubscribe anytime
Compounding means a pharmacy prepares a tailored version rather than dispensing the brand product. FDA said many ads overstated weight-loss results, understated side effects, or suggested equivalence to approved drugs.
- Save the ad, price page, and consent forms before you pay
- Write down every benefit and safety claim the ad makes
- Ask the prescriber whether the product is FDA-approved or compounded
- Ask for major risks, alternatives, total cost, and refill terms
How is DOJ pursuing health-care fraud and kickbacks?
On June 23, 2026, DOJ announced the 2026 National Health Care Fraud Takedown charging 455 defendants including 90 doctors for over $6.5 billion in alleged false claims. The operation used CMS payment suspensions, OIG exclusions, and DEA actions alongside criminal charges, according to HHS-OIG in the takedown announcement. On Aug.
10, 2026, Veloxis Pharmaceuticals agreed to pay over $46 million through a deferred prosecution and False Claims Act settlement. Prosecutors alleged meals, trips, and payments were used to induce prescriptions for Envarsus XR, including a record Open Payments penalty. The message for patients and whistleblowers is practical. Never pay a fee to get a prescription, and question free trips, large speaker fees, or pressure to stay on one brand.
What limits could reduce the promised savings?
Disclosed Pfizer and Eli Lilly contracts obtained by Public Citizen are heavily redacted and grant tariff protection. They let Lilly exclude weight-loss drugs and stop foreign sales that would create low-price benchmarks.
That means headline discounts may not reach every patient or every drug. People taking excluded products, paying cash, or using plans outside the deal channel may see little change.
You Might Also Like
- What Congress and the Courts Can Do About Trump Pharmaceutical Pricing Agreements
- Trump Pharmaceutical Pricing Agreements: Who Has Authority and Who Can Challenge It?
- Trump Pharmaceutical Pricing Agreements: Arguments From Supporters, Critics, and Legal Experts